The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.

"Drs. Youssef, Lee, Lenhardt, Park, Fernandez, and Jayaweera are employed by institutions that received research support funding from NRx Pharmaceuticals. Drs. Morganroth and Lavin are consultants to NRx Pharmaceuticals. Drs. Youssef, Lee, Lenhardt, Morganroth, and Javitt disclosed the off-label product use of Vasoactive intestinal Peptide Aviptadil. Dr. Lavin’s institution received funding from NRx Pharmaceuticals. Drs. Lavin, Schoenfeld, and Javitt received funding from NRx Pharmaceuticals. Dr. Schoenfeld received funding from Immunity Pharma; he disclosed that he has consulted with external entities unrelated to this work. Drs. Schoenfeld and Javitt disclosed work for hire. Drs. Lenhardt’s, Morganroth’s, and Jayaweera’s institutions received funding from NeuroRX. Dr. Lenhardt received funding from Merck, CSL Behring, and Trevena. Dr. Fernandez received funding from NRx Consulting. Dr. Javitt disclosed that he is an employee and shareholder of NRx Pharmaceuticals and that his spouse and children have beneficial ownership in the stock of NRx Pharmaceuticals. Dr. Jayaweera’s institution received funding from Gilead Pharmaceuticals, VIIV, and Janssen; he received support for article research from the National Institutes of Health."

"Drs. Youssef, Lee, Lenhardt, Park, Fernandez, and Jayaweera are employed by institutions that received research support funding from NRx Pharmaceuticals. Drs. Morganroth and Lavin are consultants to NRx Pharmaceuticals. Drs. Youssef, Lee, Lenhardt, Morganroth, and Javitt disclosed the off-label product use of Vasoactive intestinal Peptide Aviptadil. Dr. Lavin’s institution received funding from NRx Pharmaceuticals. Drs. Lavin, Schoenfeld, and Javitt received funding from NRx Pharmaceuticals. Dr. Schoenfeld received funding from Immunity Pharma; he disclosed that he has consulted with external entities unrelated to this work. Drs. Schoenfeld and Javitt disclosed work for hire. Drs. Lenhardt’s, Morganroth’s, and Jayaweera’s institutions received funding from NeuroRX. Dr. Lenhardt received funding from Merck, CSL Behring, and Trevena. Dr. Fernandez received funding from NRx Consulting. Dr. Javitt disclosed that he is an employee and shareholder of NRx Pharmaceuticals and that his spouse and children have beneficial ownership in the stock of NRx Pharmaceuticals. Dr. Jayaweera’s institution received funding from Gilead Pharmaceuticals, VIIV, and Janssen; he received support for article research from the National Institutes of Health."